Table 3.
Clinical and therapeutic records in our cohort.
| Variables | EP (n = 13) |
|---|---|
| Last control PASI (median (IQR)) | 10 (7–15) |
| Secukinumab responders (N (%)) | 10 (76.9) |
| Secukinumab non-responders (N (%)) | 3 (23.1) |
| Previous erythroderma episodes (N (%)) | 8 (61.5) |
| 1 | 2 (25.0) |
| 2 | 3 (37.5) |
| 3 | 1 (12.5) |
| >3 | 2 (25.0) |
| Erythroderma clearing time (median (IQR), weeks) | 3 (1–5.3) |
| PASI (median (IQR)) | |
| Week 8 | 15 (13–17) |
| PASI 75 (N (%)) | 4 (30.8) |
| PASI 90 (N (%)) | 0 (0.0) |
| PASI 100 (N (%)) | 0 (0.0) |
| Week 12 | 4.5 (0–10) |
| PASI 75 (N (%)) | 5 (38.5) |
| PASI 90 (N (%)) | 3 (23.1) |
| PASI 100 (N (%)) | 4 (30.8) |
| Week 16 | 2 (0–5) |
| PASI 75 (N (%)) | 1 (7.7) |
| PASI 90 (N (%)) | 5 (38.5) |
| PASI 100 (N (%)) | 4 (30.8) |
| Week 24 | 2 (0–2.75) |
| PASI 75 (N (%)) | 1 (7.7) |
| PASI 90 (N (%)) | 5 (38.5) |
| PASI 100 (N (%)) | 4 (30.8) |
| DLQI (median (IQR)) | |
| Week 8 | 17 (13–22) |
| Week 12 | 12 (9–17) |
| Week 16 | 11 (7–16) |
| Week 24 | 8 (6–12) |
| Week 52 | 8 (5–12) |
| Side effects (N (%)) | 5 (38.5) |
| Recurrent oral candidiasis | 1 (20.0) |
| Urticaria | 1 (20.0) |
| Injection-site pain | 3 (60.0) |
DLQI: Dermatologic Life Quality Index, EP: erythrodermic psoriasis, IQR: Interquartile range, MTX: Methotrexate, PASI: Psoriasis Area Severity Index.